Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly climbs after earnings, top analyst talks what's next for pharma giant
06:25pm, Thursday, 06'th Feb 2025
David Risinger, Leerink Partners, joins 'Fast Money' to talk Eli Lilly earnings.
Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight
03:37pm, Thursday, 06'th Feb 2025
Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year. Tirzepatide, marketed as M
Eli Lilly and Company (LLY) Q4 2024 Earnings Call Transcript
02:23pm, Thursday, 06'th Feb 2025
Eli Lilly and Company (NYSE:LLY ) Q4 2024 Results Conference Call February 6, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations David Ricks - Chair and CE
Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics
12:01pm, Thursday, 06'th Feb 2025
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates
11:50am, Thursday, 06'th Feb 2025
Eli Lilly beats fourth-quarter estimates for earnings and sales. Mounjaro and Zepbound sales miss estimates.
Weekly Jobless Claims Exceed Expectations
11:50am, Thursday, 06'th Feb 2025
Weekly Jobless Claims Exceed Expectations.
Why Eli Lilly Stock Popped on Thursday
11:29am, Thursday, 06'th Feb 2025
Eli Lilly (LLY 4.07%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report.
LLY Gains on Weight Loss Drugs, F Tariff Fears, HON Split
10:20am, Thursday, 06'th Feb 2025
Eli Lilly (LLY) shares ran higher following its earnings report with its weight loss drugs in focus. Ford Motor Co. (F) hit a 52-week low with tariffs from President Trump posing questions around the
Eli Lilly Q4 earnings beat as weight loss drug sales miss estimates
09:59am, Thursday, 06'th Feb 2025
Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates as revenue from its weight loss drugs Mounjaro and Zepbound fell short. Revenue surged
Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates
08:56am, Thursday, 06'th Feb 2025
Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago.
Novo, Lilly still leaders in obesity drug development: Barclays
08:29am, Thursday, 06'th Feb 2025
Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity drug market.
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
07:59am, Thursday, 06'th Feb 2025
On Thursday, Eli Lilly and Co LLY stock is trading higher after the company released better-than-expected fourth-quarter earnings and provided 2025 guidance.
Lilly says Mounjaro and Zepbound contributed to big revenue boost
07:50am, Thursday, 06'th Feb 2025
Lilly's CEO says that the company has “tremendous momentum” entering 2025.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
07:47am, Thursday, 06'th Feb 2025
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company expect
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
07:36am, Thursday, 06'th Feb 2025
Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates.
